How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,854 results for

Imiquimod

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Photodynamic therapy is more effective than imiquimod for actinic keratosis in organ transplant recipients - a randomized intra-individual controlled trial. Full Text available with Trip Pro

Photodynamic therapy is more effective than imiquimod for actinic keratosis in organ transplant recipients - a randomized intra-individual controlled trial. Actinic keratoses (AKs) in solid organ transplant recipients (OTRs) are difficult-to-treat premalignancies and comparison of topical therapies is therefore warranted.In an intraindividual study to compare the efficacy and safety of field treatment with methyl aminolaevulinate photodynamic therapy (MAL-PDT) and imiquimod (IMIQ) for AKs

2017 British Journal of Dermatology Controlled trial quality: uncertain

82. IRF-2 haploinsufficiency causes enhanced imiquimod-induced psoriasis-like skin inflammation. Full Text available with Trip Pro

IRF-2 haploinsufficiency causes enhanced imiquimod-induced psoriasis-like skin inflammation. IFN regulatory factor (IRF)-2 is one of the potential susceptibility genes for psoriasis, but how this gene influences psoriasis pathogenesis is unclear. Topical application of imiquimod (IMQ), a TLR7 ligand, induces psoriasis-like skin lesions in mice.The aim of this study was to investigate whether IRF-2 gene status would influence severity of skin disease in IMQ-treated mice.Imiquimod-induced (...) psoriasis-like skin inflammation was assessed by clinical findings, histology, and cytokine expression. The effects of imiquimod or IFN on peritoneal macrophages were analyzed in vitro.IMQ-induced skin inflammation assessed by clinical findings and histology was more severe in IRF-2+/- mice than in wild-type mice. In inflamed skin, mRNA expression levels of tumor necrosis factor (TNF)-α, IL-12/23p40, IL-17A, and IL-22 were significantly elevated in IRF-2+/- mice compared to wild-type mice. Stimulation

2017 Journal of dermatological science

83. Resolvin D1 attenuates imiquimod-induced mice psoriasiform dermatitis through MAPKs and NF-κB pathways. (Abstract)

Resolvin D1 attenuates imiquimod-induced mice psoriasiform dermatitis through MAPKs and NF-κB pathways. Resolvin D1 (RvD1), a pro-resolution lipid mediator derived from docosahexaenoic acid (DHA), has been described to promote several kinds of inflammatory resolution. However, the effects and anti-inflammatory mechanisms of RvD1 on psoriasis have not been previously reported.The present study aimed to determine the protective effects and the underlying mechanisms of RvD1 on imiquimod (IMQ

2017 Journal of dermatological science

84. Liver fibrosis is associated with cutaneous inflammation in the imiquimod-induced murine model of psoriasiform dermatitis. (Abstract)

Liver fibrosis is associated with cutaneous inflammation in the imiquimod-induced murine model of psoriasiform dermatitis. Psoriasis exhibits several extracutaneous manifestations. Little is known about hepatic parameters specifically associated with psoriasis.To study whether psoriasiform dermatitis is associated with liver injury.We studied liver parameters of inflammation and fibrosis in a murine model of psoriasiform dermatitis induced by topical application of imiquimod for 9 weeks.Topical (...) treatment with imiquimod induced a form of psoriasiform dermatitis reminiscent of the human disorder, characterized by thickened and scaly skin, psoriasiform epidermal hyperplasia, altered keratinocyte differentiation and cutaneous overexpression of interleukin-17A. Mice with dermatitis displayed hepatitis, as shown by elevation of plasma transaminase levels, as well as portal and periportal hepatitis, characterized by T-lymphocyte (CD3ε+ ) and polymorphonuclear cell (Gr1+ ) infiltrates. The hepatitis

2017 British Journal of Dermatology

85. Preliminary stop of the TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC) trial. Full Text available with Trip Pro

Preliminary stop of the TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC) trial. The "TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia" (TOPIC) trial was stopped preliminary, due to lagging inclusions. This study aimed to evaluate the treatment efficacy and clinical applicability of imiquimod 5% cream in high-grade cervical intraepithelial neoplasia (CIN). The lagging inclusions were mainly due to a strong patient preference (...) for either of the two treatment modalities. This prompted us to initiate a new study on the same subject, with a non-randomized, open-label design: the 'TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC)-3' study. Original TOPIC-trial: Medical Ethics Committee approval number METC13231; ClinicalTrials.gov Identifier: NCT02329171, 22 December 2014. TOPIC-3 study: Medical Ethics Committee approval number METC162025; ClinicalTrials.gov Identifier: NCT02917746, 16 September

2017 BMC Cancer

86. Lymphoedema in Lentigo Maligna patients treated with imiquimod, a long term adverse effect. Full Text available with Trip Pro

Lymphoedema in Lentigo Maligna patients treated with imiquimod, a long term adverse effect. 29274234 2018 06 13 1365-2133 178 6 2018 Jun The British journal of dermatology Br. J. Dermatol. Lymphoedema in patients with lentigo maligna treated with imiquimod: a long-term adverse effect. 1441-1442 10.1111/bjd.16267 Tio D D http://orcid.org/0000-0002-9819-1612 Vrije Universiteit Medical Center, Amsterdam, the Netherlands. Kirtschig G G University Hospital of Marburg, Marburg, Germany. Hoekzema R R

2017 British Journal of Dermatology

87. A real-world, community-based cohort study comparing the effectiveness of topical fluoruracil vs. topical imiquimod for the treatment of actinic keratosis. Full Text available with Trip Pro

A real-world, community-based cohort study comparing the effectiveness of topical fluoruracil vs. topical imiquimod for the treatment of actinic keratosis. The most widely used topical agents for the field-based treatment of multiple actinic keratoses (AKs) are 5-fluorouracil and imiquimod, but their comparative effectiveness has not been assessed in a real-world setting.We compared the effectiveness of 5-fluorouracil and imiquimod in reducing risk for subsequent AKs in a large, integrated (...) health care delivery system in northern California.In this cohort study, we identified adult health plan members who had an AK diagnosed in 2007 and who subsequently filled a prescription for 5-fluorouracil or imiquimod (N = 5700). We followed subjects for subsequent AKs identified by the International Classification of Diseases codes and estimated the 2-year (short-term) and 5-year (long-term) differences in cumulative risk while controlling for potential confounding by pretreatment variables.5

2017 Journal of American Academy of Dermatology

88. High fat diet exacerbates imiquimod-induced psoriasis-like dermatitis in mice. (Abstract)

High fat diet exacerbates imiquimod-induced psoriasis-like dermatitis in mice. Psoriasis, a chronic inflammatory skin disease, is closely related to systemic metabolism. An elevated body mass index (BMI) is a risk factor for psoriasis; inflammasomes are activated by adipose tissue macrophages in obese subjects. We hypothesized that hyperlipidaemia is involved in the pathogenesis of psoriasis and examined the role of a high-fat diet (HFD) in the development of psoriasis in imiquimod (IMQ

2017 Experimental Dermatology

89. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical imiquimod and topical 5-fluorouracil in patients with superficial basal cell carcinoma. Full Text available with Trip Pro

Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical imiquimod and topical 5-fluorouracil in patients with superficial basal cell carcinoma. For the treatment of superficial basal cell carcinoma, a prospective, noninferiority, randomized controlled multicenter trial with 601 patients showed that 5% imiquimod cream was superior and 5-fluorouracil cream not inferior to methyl aminolevulinate photodynamic therapy (MAL-PDT) at 1 and 3 years (...) after treatment. No definite conclusion could be drawn regarding the superiority of imiquimod over 5-fluorouracil. We now present the 5-year follow-up results according to the intention-to-treat analysis. Five years after treatment, the probability of tumor-free survival was 62.7% for methyl aminolevulinate photodynamic therapy (95% confidence interval [CI] = 55.3-69.2), 80.5% for imiquimod (95% CI = 74.0-85.6), and 70.0% for 5-fluorouracil (95% CI = 62.9-76.0). The hazard ratio for treatment

2017 Journal of Investigative Dermatology

90. Protocol for the TIDAL Melanoma Study: topical imiquimod or diphenylcyclopropenone for the management of cutaneous in-transit melanoma metastases-a phase II, single centre, randomised, pilot study. Full Text available with Trip Pro

Protocol for the TIDAL Melanoma Study: topical imiquimod or diphenylcyclopropenone for the management of cutaneous in-transit melanoma metastases-a phase II, single centre, randomised, pilot study. Patients with in-transit melanoma metastases present a therapeutic challenge. Complete surgical excision of localised disease is considered as the gold standard; however, surgery is not always acceptable and alternatives are required. Treatment results reported using imiquimod (...) and diphenylcyclopropenone (DPCP) suggest that topical immunotherapies can be used to successfully treat select patients with melanoma metastases. A phase II, randomised, single centre, pilot study was designed to assess the clinical efficacy and safety of DPCP and imiquimod for the treatment of superficial, cutaneous in-transit melanoma metastases.This is an open-label, non-superiority, pilot study with no treatment cross-over. Eligible patients are randomised in a 1:1 ratio to receive topical therapy for up to 12

2017 BMJ open Controlled trial quality: uncertain

91. Long-Term Follow-Up Results of Topical Imiquimod Treatment in Basal Cell Carcinoma. (Abstract)

Long-Term Follow-Up Results of Topical Imiquimod Treatment in Basal Cell Carcinoma. Imiquimod 5% topical cream is approved for treatment of superficial basal cell carcinoma (BCC). Data on the long-term efficacy and usage in other BCC subtypes are scarce.Evaluation of long-term safety and efficacy of topical imiquimod treatment in various BCC subtypes and locations, with individualized treatment duration.Histopathologically confirmed BCCs treated solely with topical imiquimod were identified (...) retrospectively and included in this study. Clinical and histopathologic tumor clearances were the primary end point. After treatment was concluded, patients were examined every 3 to 6 months.In total, 24 BCC samples from 22 patients (F:M = 9:13; mean age: 73.5 years, SD: 10.767) were evaluated. The majority of the lesions were located in the head and neck area (83%). Mean treatment duration until complete clearance was 15.7 ± 6.9 weeks (6-28 weeks). Imiquimod was discontinued in 3 lesions, due to either

2017 Dermatologic Surgery

92. The TLR7 agonist imiquimod induces anti-cancer effects via autophagic cell death and enhances anti-tumoral and systemic immunity during radiotherapy for melanoma Full Text available with Trip Pro

The TLR7 agonist imiquimod induces anti-cancer effects via autophagic cell death and enhances anti-tumoral and systemic immunity during radiotherapy for melanoma Toll-like receptor (TLR) ligands are strongly considered immune-adjuvants for cancer immunotherapy and have been shown to exert direct anti-cancer effects. This study was performed to evaluate the synergistic anti-cancer and anti-metastatic effects of the TLR7 agonist imiquimod (IMQ) during radiotherapy for melanoma. The pretreatment

2017 Oncotarget

93. Vitiligo or Vitiligo-like Hypopigmentation Associated with Imiquimod Treatment of Condyloma Acuminatum: Not a Casual Event Full Text available with Trip Pro

Vitiligo or Vitiligo-like Hypopigmentation Associated with Imiquimod Treatment of Condyloma Acuminatum: Not a Casual Event 28218231 2017 03 20 2018 12 02 2542-5641 130 4 2017 02 20 Chinese medical journal Chin. Med. J. Vitiligo or Vitiligo-like Hypopigmentation Associated with Imiquimod Treatment of Condyloma Acuminatum: Not a Casual Event. 503-504 10.4103/0366-6999.199846 Long Fu-Quan FQ STD Institute, Shanghai Dermatology Hospital, Shanghai 200443, China. Zhao Li-Shi LS STD Institute (...) , Shanghai Dermatology Hospital, Shanghai 200443, China. Qian Yi-Hong YH STD Institute, Shanghai Dermatology Hospital, Shanghai 200443, China. eng Letter China Chin Med J (Engl) 7513795 0366-6999 0 Aminoquinolines P1QW714R7M Imiquimod IM Adult Aminoquinolines adverse effects therapeutic use Condylomata Acuminata drug therapy Female Humans Hypopigmentation chemically induced diagnosis Imiquimod Male Middle Aged Vitiligo chemically induced diagnosis 2017 2 21 6 0 2017 2 22 6 0 2017 3 21 6 0 ppublish

2017 Chinese medical journal

94. Complement C3 Exacerbates Imiquimod-Induced Skin Inflammation and Psoriasiform Dermatitis Full Text available with Trip Pro

Complement C3 Exacerbates Imiquimod-Induced Skin Inflammation and Psoriasiform Dermatitis 27876407 2018 07 16 2018 12 02 1523-1747 137 3 2017 03 The Journal of investigative dermatology J. Invest. Dermatol. Complement C3 Exacerbates Imiquimod-Induced Skin Inflammation and Psoriasiform Dermatitis. 760-763 S0022-202X(16)32652-5 10.1016/j.jid.2016.11.011 Giacomassi Chiara C Centre for Complement and Inflammation Research, Department of Medicine, Imperial College London, London, UK. Buang (...) /L022699/1 Medical Research Council United Kingdom 108008/Z/15/Z Wellcome Trust United Kingdom Letter Research Support, Non-U.S. Gov't 2016 11 19 United States J Invest Dermatol 0426720 0022-202X 0 Adjuvants, Immunologic 0 Aminoquinolines 0 C3 protein, human 0 Complement C3 P1QW714R7M Imiquimod IM Adjuvants, Immunologic adverse effects Aminoquinolines adverse effects Complement Activation Complement C3 metabolism Dermatitis etiology immunology metabolism Humans Imiquimod Immunity, Cellular Skin drug

2017 The Journal of investigative dermatology

95. Imiquimod has strain-dependent effects in mice and does not uniquely model human psoriasis Full Text available with Trip Pro

Imiquimod has strain-dependent effects in mice and does not uniquely model human psoriasis Imiquimod (IMQ) produces a cutaneous phenotype in mice frequently studied as an acute model of human psoriasis. Whether this phenotype depends on strain or sex has never been systematically investigated on a large scale. Such effects, however, could lead to conflicts among studies, while further impacting study outcomes and efforts to translate research findings.RNA-seq was used to evaluate

2017 Genome medicine

96. Use of topical imiquimod in the treatment of VIN: a case report and review of the literature Full Text available with Trip Pro

Use of topical imiquimod in the treatment of VIN: a case report and review of the literature Vulvar intraepithelial neoplasia (VIN) is a premalignant disease of the vulvar squamous epithelium. Standard treatment for VIN lesions is surgical excision. Alternative therapeutic options for conservative treatment have been sought by patients to prevent disfigurement and to preserve sexual function. We present such a patient in whom topical imiquimod was used with a successful outcome. Imiquimod

2016 International journal of women's dermatology

97. Combination of imiquimod with cryotherapy in the treatment of penile intraepithelial neoplasia Full Text available with Trip Pro

Combination of imiquimod with cryotherapy in the treatment of penile intraepithelial neoplasia 29264388 2019 02 26 2352-5126 3 6 2017 Nov JAAD case reports JAAD Case Rep Combination of imiquimod with cryotherapy in the treatment of penile intraepithelial neoplasia. 546-549 10.1016/j.jdcr.2017.07.018 Shaw Katharina S KS Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Nguyen Giang H GH Department of Dermatology, Anschultz Medical Campus (...) cryotherapy imiquimod penile intraepithelial neoplasia 2017 12 22 6 0 2017 12 22 6 0 2017 12 22 6 1 epublish 29264388 10.1016/j.jdcr.2017.07.018 S2352-5126(17)30168-6 PMC5728708 Ther Clin Risk Manag. 2008 Oct;4(5):1085-95 19209288 Lancet Infect Dis. 2001 Oct;1(3):189-98 11871495 Dermatol Surg. 2008 Jul;34(7):878-83 18363722 Arch Dermatol. 1986 Oct;122(10):1124-6 3767398 BJU Int. 2005 Jun;95(9):1187-91 15892798 BMJ. 2013 Mar 06;346:f1149 23468288 Eur Urol. 2012 Nov;62(5):923-8 22421082 Br J Dermatol. 2002

2017 JAAD Case Reports

98. Efficacy of fulguration combined with imiquimod cream on condyloma acuminatum, and the effect on immune functions and serums levels of IL-2 and IL-10 Full Text available with Trip Pro

Efficacy of fulguration combined with imiquimod cream on condyloma acuminatum, and the effect on immune functions and serums levels of IL-2 and IL-10 The objective of the present study was to investigate the clinical efficacy of high-frequency fulguration combined with 5% imiquimod cream for condyloma acuminatum (CA), and the effect on T cell immune function and serum levels of interleukin (IL)-2 and IL-10. We enrolled 112 patients with CA between January 2014 and January 2016. Patients were (...) randomly divided into the control group (n=56) and observation group (n=56). The control group received high-frequency fulguration combined with intramuscular injection of Bacillus Calmette-Guérin polysaccharide nucleic acid, and the observation group received high-frequency fulguration combined with external application of 5% imiquimod cream. In both groups, the course of treatment lasted for 12 weeks, and the follow-up period was 6 months. Clinical efficacy was compared between the groups. The total

2017 Experimental and therapeutic medicine Controlled trial quality: uncertain

99. Therapy with transcutaneous administration of imiquimod combined with oral administration of sorafenib suppresses renal cell carcinoma growing in an orthotopic mouse model Full Text available with Trip Pro

Therapy with transcutaneous administration of imiquimod combined with oral administration of sorafenib suppresses renal cell carcinoma growing in an orthotopic mouse model Imiquimod is an imidazoquinoline immune response modifier that is used in antiviral and antiallergic creams. Combination therapy using transcutaneous imiquimod and oral sorafenib was previously demonstrated to reduce the tumor burden of renal cell carcinoma growing cutaneously in a mouse model. In the present study (...) , an orthotopic mouse model was used to investigate whether combined treatment with oral sorafenib and transcutaneous imiquimod inhibited renal cell carcinoma growing in the kidney. Kidneys of female BALB/c mice were orthotopically implanted with RENCA mouse kidney cancer cells, and the mice were transcutaneously treated with cream containing imiquimod and/or with orally administered sorafenib 5 days following cell implantation. Tumor burden and incidence were determined 28 days following the start of therapy

2017 Oncology letters

100. The Paget Trial: A Multicenter, Observational Cohort Intervention Study for the Clinical Efficacy, Safety, and Immunological Response of Topical 5% Imiquimod Cream for Vulvar Paget Disease Full Text available with Trip Pro

The Paget Trial: A Multicenter, Observational Cohort Intervention Study for the Clinical Efficacy, Safety, and Immunological Response of Topical 5% Imiquimod Cream for Vulvar Paget Disease Vulvar Paget disease is a rare skin disorder, which is most common in postmenopausal Caucasian women. They usually present with an erythematous plaque that may show fine or typical "cake icing" scaling or ulceration that may cause itching, pain, irritation, or a burning sensation. Although most cases (...) % to 70%, which emphasizes the need for new treatment options. A number of case reports, retrospective case series, and one observational study have shown promising results using the topical immune response modifier imiquimod.This study aims to investigate the efficacy, safety, and immunological response in patients with noninvasive vulvar Paget disease using a standardized treatment schedule with 5% imiquimod cream.Topical 5% imiquimod cream might be an effective and safe treatment alternative

2017 JMIR Research Protocols

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>